Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria, tetanus, and acellular pertussis + Haemophilus influenzae type b combined vaccine
- Development stage
- Unknown
- Lead developer
- Yuxi Watson Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria, tetanus, and acellular pertussis + Haemophilus influenzae type b combined vaccine (DTaP-Hib) is a multi-component combination vaccine being developed by Yuxi Watson Biotechnology. It is designed to provide active immunization against four major pediatric infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and invasive infections caused by Haemophilus influenzae type b. The formulation consists of diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens (including pertussis toxoid and filamentous hemagglutinin), combined with a Hib capsular polysaccharide conjugate, all adsorbed onto an aluminum-based adjuvant to enhance the immune response. As of 2023, the vaccine is undergoing Phase I clinical evaluation in China to assess its safety and immunogenicity in a broad age range, including infants, children, and adults.
- Other names
- adsorbed acellular DTaP-Hib combined vaccineDTaP-Hib vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on adsorbed acellular diphtheria, tetanus, and acellular pertussis + Haemophilus influenzae type b combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria, tetanus, and acellular pertussis + Haemophilus influenzae type b combined vaccine.